US biotechnology company Moderna announced Sunday (31) that authorities have delayed licensing its covid-19 vaccine for teenagers, in order to buy more time to better assess potential risks of myocarditis, or carditis.
“Moderna’s agency requires additional time to evaluate recent international analyzes of the risk of developing post-vaccination myocarditis,” the company explained in a statement.
The company anticipates that evaluation to determine whether Moderna’s vaccine should be recommended for 12-17 year olds will continue through January 2022.
Myocarditis and its associated risk, pericarditis (inflammation around the heart) has been previously linked to Pfizer and Moderne’s antiviral vaccines, particularly among adolescents and young adults.
However, the risk is much higher after contracting the COVID-19 virus, according to a study published in August by the US Centers for Disease Control and Prevention (CDC).
Moderna said the CDC found that “myocarditis after immunization with mRNA vaccines was unusual and generally mild.”
Another mRNA vaccine, Pfizer-BioNTech, received US approval Friday for children ages 5 to 11, in lower doses than in adults.
know more
+ Influencer disrupts Instagram after reviews for photoshoot next to Dad’s coffin
+ Video: Blogger accused of distracting guard about mother’s escape from prison
+ Amazon driver shot after woman caught driving out of backyard
+ 20 Best Selling Pickup Trucks in 2021
+ Expedition identified the giant squid responsible for the shipwreck in 2011
+ Everything you need to know before buying a cooking pot
+ Sprinter becomes a fully mobile home; meet the model
+ Doctors find a piece of cement in the patient’s heart during surgery
+ The shark was caught in MA with the remains of the young lost in the stomach
US agency warns: Never wash raw chicken
+ Attacks passengers and pulls out a host’s teeth
+ Aloe vera gel in the drink: see the benefits
+ Lemon Squeeze Trick Goes Crazy On Social Media
+ Yasmine Brunet breaks the silence